Chia-Jui Yen
Chia-Jui Yen
Education Background
National Cheng Kung University, Tainan, Taiwan
Institute of Clinical Medicine, PhD
National Yan-Ming University, Taipei, Taiwan
College of Medicine, MD
Experience & Position
2023/02-now - Director of Department of Oncology, National Cheng Kung University, Tainan, Taiwan
2020/08-now Director of Cancer Center, National Cheng Kung University Hospital
2018/08- now Professor, Department of Oncology, College of Medicine, National Cheng Kung University, Tainan, Taiwan
2015/02-2018/07 Associate professor, Department of Internal Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan
2008/07-2015/02 Assistant professor, Department of Internal Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan
2002/07-2008/07 Attending Physician, Medical oncology and hematology, National Cheng Kung University Hospital, Tainan, Taiwan
2000/07-2002/07 Fellowship, Medical oncology and hematology, National Cheng Kung University Hospital, Tainan, Taiwan
1997/07-2000/07 Residency, Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan
Fields of specialty: Professional Licensure and Membership
2004– Specialist of Hematology The Hematology Society of Taiwan
2004– Specialist of Hospice Palliative Medicine Taiwan Academy of Hospice Palliative Medicine
2002– The board of Medical Oncology The Chinese Oncology Society
2000– Specialist of Internal medicine Taiwan Society of Internal Medicine
Publications:
1. Liu IT, Yen CS, Wang WL, Tsai HW, Chu CY, Chang MY, Hou YF, Yen CJ*. (10, 2021). Predict Early Recurrence of Resectable Hepatocellular Carcinoma Using Multi-imensional Artificial Intelligence Analysis of Liver Fibrosis. Cancers; 13(21):5323-5323.
2. Chen RY, Yen CJ*, Lin YJ, Wang JM, Tasi TF, Huang YC, Liu YW, Tsai HW, Lee MH, Hung LY. (10, 2021). CPAP enhances and maintains chronic inflammation in hepatocytes to promote hepatocarcinogenesis. Cell Death ＆Disease; 12(11):983-983.
3. Yen CC, Shan YS, Chao YJ, Liao TK, Chen IS, Huang HY, Liu IT, Yen CJ*. (07, 2021). Surgery alone, adjuvant tegafur/gimeracil/octeracil (S-1), or platinum-based chemotherapies for resectable gastric cancer: real-world experience and a propensity score matching analysis. BMC Cancer. 9;21(1):796. doi: 10.1186/s12885-021-08487-z.PMID: 34243732
4. Yen CC, Yen CJ*.(02, 2022). Safety of ramucirumab treatment in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein. Expert Opinion on Drug Safety. 28;1-10. doi: 10.1080/14740338.2022.1995353.
5.Yen CJ*, Hung CH, Tsai WM, Cheng HC, Yang HL, Lu YJ, Tsai KL (2020, Aug). Effect of Exercise Training on Exercise Tolerance and Level of Oxidative Stress for Head and Neck Cancer Patients Following Chemotherapy. Frontiers in Oncology, 10:1536-1536.
6.Yen CJ*, Kudo M, Lim H Y, Hsu CH, Vogel A, Brandi G, Cheng R, Nitu IS, Abada P, Hsu Y, Zhu AX, Kang YK. (2020, Aug). Efficacy and Safety of Ramucirumab in Asian and Non-Asian Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Individual Data Analysis of Two Randomized Studies. Liver Cancer, 9(4):440-454.
7.Desai J, Deva S, Lee JS, Lin CC, Yen CJ, Chao Y, Keam B, Jameson M, Hou MM, Kang YK, Markman B, Lu CH, Rau KM, Lee KH, Horvath L, Friedlander M, Hill A, Sandhu S, Barlow P, Wu CY, Zhang Y, Liang L, Wu J, Paton V, Millward M (2020, Jun). Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors. Journal for ImmunoTherapy of Cancer, 8(1):e000453-e000453.
8.Yen CJ*, Kiyota N, Hanai N, Takahashi S, Yokota T, Iwae S, Shimizu Y, Hong RL, Goto M, Kang JH, Li WSK, Ferris RL, Gillison M, Endo T, Jayaprakash V, Tahara M (2020, Jun). Two-year follow-up of a randomized phase III clinical trial of nivolumab vs. the investigator’s choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141). Head and Neck, 42(10):2852-2862.
9.Chen RY, Yen CJ, Liu YW, Guo CG, Weng CY, Lai CH, Wang YM, Lin YJ, Hung LY (2020, Apr). CPAP promotes angiogenesis and metastasis by enhancing STAT3 activity. Cell Death and Differentiation, 27(4):1259-1273.
10.Lai CH, Chen RY, Hsieh HP, Tsai SJ, Chang KC, Yen CJ, Huang YC, Liu YW, Lee JC, Lai YC, Hung LY, Lin BW (2020, Mar). A selective Aurora-A 5’-UTR siRNA inhibits tumor growth and metastasis. Cancer Letters, 472:97-107.
11.Liao WY, Hsu CC, Chan TS, Yen CJ, Chen WY, Pan HW, Tsai KK (2020, Mar). Dishevelled 1-Regulated Superpotent Cancer Stem Cells Mediate Wnt Heterogeneity and Tumor Progression in Hepatocellular Carcinoma. Stem Cell Reports, 14(3):462-477.
12.Yen CJ*, Tsou HH, Hsieh CY, Chu CY, Chiu CF, Chen CC, Tsao CJ, Tsai KY, Tsai ST, Chang JY, Chang KY (2019, Jun). Sequential therapy of neoadjuvant biochemotherapy with cetuximab, paclitaxel, and cisplatin followed by cetuximab-based concurrent bioradiotherapy in high-risk locally advanced oral squamous cell carcinoma: Final analysis of a phase 2 clinical trial. Head and Neck, 41(6):1703-1712.
13.Yen CJ*, Yang ST, Chen RY, Huang W, Chayama K, Lee MH, Yang SJ, Lai HS, Yen HY, Hsiao YW, Wang JM, Lin YJ, Hung LY (2019, Jun). Hepatitis B virus X protein (HBx) enhances centrosomal P4.1-associated protein (CPAP) expression to promote hepatocarcinogenesis. Journal of Biomedical Science, 26(1):44-44.
14.Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, Assenat E, Brandi G, Pracht M, Lim HY, Rau KM, Motomura K, Ohno I, Merle P, Daniele B, Shin DB, Gerken G, Borg C, Hiriart JB, Okusaka T, Morimoto M, Hsu Y, Abada PB, Kudo M; REACH-2 study investigators (2019, Feb). Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations
(REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, 20(2):282-296.
15.Lim HY, Merle P, Weiss KH, Yau TC, Ross P, Mazzaferro V, Blanc JF, Ma YT, Yen CJ, Kocsis J, Choo SP, Sukeepaisarnjaroen W, Gérolami R, Dufour JF, Gane E, Ryoo BY, Peck-Radosavljevic M, Dao T, Yeo W, Lamlertthon W, Thongsawat S, Teufel M, Roth K, Reis D, Childs BH, Krissel H, Llovet JM (2018, Oct). Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-mutated Hepatocellular Carcinoma. Clinical Cancer Research, 24(19):4650-4661.
16.Yen CJ*, Ai YL, Tsai HW, Chan SH, Yen CS, Cheng KH, Lee YP, Kao CW, Wang YC, Chen YL, Lin CH, Liu T, Tsai HP, Wang JR, Su IJ, Huang W (2018, Sep). Hepatitis B virus surface gene pre-S2 mutant as a high-risk serum marker for hepatoma recurrence after curative hepatic resection. Hepatolgy, 68(3):815-826.
17.Shitara K, Özgüroğlu M, Bang YJ, Bartolomeo MD, Mandalà M, Ryu MH, Fornaro L, Olesiński T, Caglevic C, Chung HC, Muro K, Goekkurt E, Mansoor W, McDermott RS, Shacham-Shmueli E, Chen X, Mayo C, Kang SP, Ohtsu A, Fuchs CS; KEYNOTE-061 investigators (2018, Jul). Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet, 392:123-133.
18.Wu SY, Lan SH, Wu SR, Chiu YC, Lin XZ, Su IJ, Tsai TF, Yen CJ, Lu TH, Liang FW, Li CY, Su HJ, Su CL, Liu HS (2018, Jul). Hepatocellular carcinoma-related cyclin D1 is selectively regulated by autophagy degradation system. Hepatology, 68(1):141-154.
19.Yen CJ*, Muro K, Kim TW, Kudo M, Shih JY, Lee KW, Chao Y, Kim SW, Yamazaki K, Sohn J, Cheng R, Zhang Y, Binder P, Mi G, Orlando M, Chung HC (2018, Jul). Ramucirumab Safety in East Asian Patients: A Meta-Analysis of Six Global, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trials. Journal of Global Oncology, 4:1-12.
20.Yen CJ*, Kim TY, Feng YH, Chao Y, Lin DY, Ryoo BY, Huang D.CL, Schnell D, Hocke J, Loembé AB, Cheng AL (2018, May). A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma. Liver Cancer, 7(2):165-178.
21.Kim TY, Yen CJ, Al-Batran SE, Ferry D, Gao L, Hsu Y, Cheng R, Orlando M, Ohtsu A (2018, Mar). Exposure-response relationship of ramucirumab in East Asian patients from RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer. Gastric Cancer, 21(2):276-284.
22.Kim TY, Yen CJ, Al-Batran SE, Ferry D, Gao L, Hsu Y, Cheng R, Orlando M, Ohtsu A. (2018, Mar). Exposure-response relationship of ramucirumab in East Asian patients from RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer. Gastric Cancer, 21(2):276-284.
23.Chau I, Peck-Radosavljevic M, Borg C, Malfertheiner P, Seitz JF, Park JO, Ryoo BY, Yen CJ, Kudo M, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Okusaka T, Bowman L, Cui ZL, Girvan AC, Abada PB, Yang L, Zhu AX. (2017, Aug). Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study. European Journal of Cancer, 81:17-25.
24.Yau TCC, Lencioni R, Sukeepaisarnjaroen W, Chao Y, Yen CJ, Lausoontornsiri W, Chen PJ, Sanpajit T, Camp A, Cox DS, Gagnon RC, Liu Y, Raffensperger KE, Kulkarni DA, Kallender H, Ottesen LH, Poon RTP, Bottaro DP. (2017, May). A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma. Clinical Cancer Research, 23(10):2405-2413.
25.Zhu AX, Baron AD, Malfertheiner P, Kudo M, Kawazoe S, Pezet D, Weissinger F, Brandi G, Barone CA, Okusaka T, Wada Y, Park JO, Ryoo BY, Cho JY, Chung HC, Li CP, Yen CJ, Lee KD, Chang SC, Yang L, Abada PB, Chau I. (2017, Feb). Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma: Analysis of REACH Trial Results by Child-Pugh Score. JAMA Oncology, 3(2):235-243.
26.Lu CY, Chen SY, Peng HL, Kan PY, Chang WC, Yen CJ*. (2017, Jan). Cell-free methylation makers with diagnostic and prognostic potential in hepatocellular carcinoma. Oncotarget, 8(4):6406-6418. *Corresponding author.
27.Chan TS, Hsu CC, Pai VC, Liao WY, Huang SS, Tan KT, Yen CJ, Hsu SC, Chen WY, Shan YS, Li CR, Lee MT, Jiang KY, Chu JM, Lien GS, Weaver VM, Tsai KK (2016, Dec). Metronomic chemotherapy prevents therapy-induced stromal activation and induction of tumor-initiating cells. Journal of Experimental Medicine, 213(13):2967-2988.
28.Chen HA, Kuo TC, Tseng CF, Ma JT, Yang ST, Yen CJ, Yang CY, Sung SY, Su JL (2016, Nov). Angiopoietin-like protein 1 antagonizes MET receptor activity to repress sorafenib resistance and cancer stemness in hepatocellular carcinoma. Hepatology, 64(5):1637-1651.
29.Wu YH, Yen CJ*, Hsiao JR, Ou CY, Huang JS, Wong TY, Tsai ST, Huang CC, Lee WT, Chen KC, Fang SY, Wu JL, Hsueh WT, Lin FC, Yang MW, Chang JY, Liao HC, Wu SY, Lin CL, Wang YH, Weng YL, Yang HC, Chen YS, Chang JS (2016, Oct). A Comprehensive Analysis on the Association between Tobacco-Free Betel Quid and Risk of Head and Neck Cancer in Taiwanese Men. PLoS One, 11(10):e0164937.
30.Abou-Alfa GK, Puig O, Daniele B, Kudo M, Merle P, Park JW, Ross P, Peron JM, Ebert O, Chan S, Poon TP, Colombo M, Okusaka T, Ryoo BY, Minguez B, Tanaka T, Ohtomo T, Ukrainskyj S, Boisserie F, Rutman O, Chen YC, Xu C, Shochat E, Jukofsky L, Reis B, Chen G, Di Laurenzio L, Lee R, Yen CJ* (2016, Aug). Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma. Journal of Hepatology, 65(2):289-295. *Corresponding author.
31.Yen CS, Su ZR, Lee YP, Liu IT, Yen CJ* (2016, Jun). miR-106b promotes cancer progression in hepatitis B virus-associated hepatocellular carcinoma.. World Journal of Gastroenterology, 22(22):5183-5192. *Corresponding author.
32.Hung CL, Yen CS, Tsai HW, Su YC, Yen CJ* (2015, Oct). Upregulation of MicroRNA-19b predicts good prognosis in patients with hepatocellular carcinoma presenting with vascular invasion or multifocal disease. BMC Cancer, 15:665-1-665-10. *Corresponding author.
33.Chen WS, Yen CJ*, Chen YJ, Chen JY, Wang LY, Chiu SJ, Shih WL, Ho CY, Wei TT, Pan HL, Chien PH, Hung MC, Chen CC, Huang WC (2015, Sep). miRNA-7/21/107 contribute to HBx-induced hepatocellular carcinoma progression through suppression of maspin. Oncotarget, 6(28):25962-74.